We developed a simplified microarray test for detecting and identifying mutations in rpoB, katG, inhA, embB, and rpsL and compared the analytical performance of the test to that of phenotypic drug susceptibility testing (DST). The analytical sensitivity was estimated to be at least 110 genome copies per amplification reaction. The microarray test correctly detected 95.2% of mutations for which there was a sequence-specific probe on the microarray and 100% of 96 wild-type sequences. M ycobacterium tuberculosis infects one-third of the world's population, with approximately nine million new cases and two million deaths attributable to the disease each year (1). Early case detection and rapid treatment are considered the most effective control strategies to reduce M. tuberculosis transmission (2), especially in cases involving multidrug-resistant (MDR) or extensively drug-resistant (XDR) M. tuberculosis. Culture-based methods remain the gold standard for diagnosing drug-resistant M. tuberculosis but can take several weeks or months to complete. Thus, nucleic acid-based drug susceptibility tests are becoming increasingly attractive as diagnostic tools in order to initiate individualized, patient-appropriate treatment in a timely manner.
M
ycobacterium tuberculosis infects one-third of the world's population, with approximately nine million new cases and two million deaths attributable to the disease each year (1) . Early case detection and rapid treatment are considered the most effective control strategies to reduce M. tuberculosis transmission (2) , especially in cases involving multidrug-resistant (MDR) or extensively drug-resistant (XDR) M. tuberculosis. Culture-based methods remain the gold standard for diagnosing drug-resistant M. tuberculosis but can take several weeks or months to complete. Thus, nucleic acid-based drug susceptibility tests are becoming increasingly attractive as diagnostic tools in order to initiate individualized, patient-appropriate treatment in a timely manner.
Technologies such as Cepheid's GeneXpert and Hain line probe assays reduce the time to diagnosis for many tuberculosis (TB) patients, provide a rapid read-out indicating resistance to rifampin or selected mutations conferring resistance to other firstor second-line drugs, and illustrate the potential to deploy molecular tests closer to the point of need (3) . However, the number of known genes and mutations conferring resistance to first-and second-line drugs greatly exceeds the multiplexing capacity of these platforms, which may limit their clinical efficacy in the treatment and control of multidrug-resistant or extensively drug-resistant TB. Planar and suspension microarrays are well suited to address the multiple-gene, multiple-mutation challenge of diagnosing drug-resistant TB (4) (5) (6) (7) (8) (9) (10) (11) (12) , but clinical adoption of microarray technology is hampered by poor reproducibility (13) (14) (15) , complex workflows, and/or extensive user subjectivity and involvement in image and data analysis (16) . In order to translate microarrays into efficacious TB diagnostics at the point of need, it is therefore necessary to simplify user interaction with the technology while retaining the ability to detect multiple genes and multiple mutations in a timely manner. The objectives of this study were to develop a gel element microarray test for MDR TB at a level of coverage surpassing what is currently available with WHO-endorsed molecular platforms, estimate the analytical specificity of the test on M. tuberculosis isolates of known genotype and phenotype, and compare the performance of the test to that of conventional drug susceptibility testing as a precursor to integrating the method into an entirely closed-amplicon consumable (17, 18) and sample-to-answer system.
MATERIALS AND METHODS
Isolates and positive controls. The set of M. tuberculosis isolates and nucleic acids utilized for this study represents a global and historical distribution of drug-susceptible, drug-resistant, and MDR strains. Materials from the Centers for Disease Control and Prevention (CDC, Atlanta, GA) and the TDR Tuberculosis Strain Bank (19) were provided as heat-killed crude lysates. Available isolates covered only 22 of 39 resistance-conferring mutations that were present on the gel element array. Purified DNA from M. tuberculosis H37Ra was acquired from the American Type Culture Collection (ATCC, Manassas, VA) and quantified on a Nanodrop 3000 fluorometer before use. CDC and TDR materials were used to verify the analytical specificity of microarray probes before verification of array performance on blinded samples from the Johns Hopkins Hospital (JHH) clinical isolate archive. M13mp18 single-stranded DNA was purchased from New England BioLabs (Ipswich, MA) and diluted to 250 pg ml Ϫ1 in 10 mM Tris, 1 mM Na 2 EDTA (pH 7.5). Crude lysates and purified nucleic acids were stored at Ϫ20°C until use.
The JHH M. tuberculosis isolate archive consists of susceptible, monoresistant, MDR, and XDR M. tuberculosis strains from the midAtlantic, south, and southwest regions of the United States as well as from Mexico, South America, Cameroon, and Kazakhstan. Isolates used for this study were collected between 1995 and 2011. JHH isolates were cultivated under biosafety level 3 (BSL-3) conditions on Lowenstein-Jensen (L-J) agar slants and maintained at 37°C in 5% CO 2 . Crude lysates were prepared from each strain by harvesting a small amount of cells from L-J slants, resuspending the cells in Middlebrook 7H9 broth, and adjusting the turbidity to a 0.5 McFarland standard (ca. 1.5 ϫ 10 8 CFU ml Ϫ1 ). Subsequently, 1 ml of each standardized suspension was centrifuged for 5 min at 13,000 ϫ g, and the supernatant was removed. Cell pellets were resuspended in 200 l of molecular-grade water, heat killed at 95°C for 30 min, sonicated for 15 min, and centrifuged for 5 min at 13,000 ϫ g. A 100-l aliquot of each supernatant was then removed and stored at Ϫ20°C until use, representing approximately 7.5 ϫ 10 7 CFU equivalents of bacteria and 3.3 ng DNA l Ϫ1 , assuming a genome size of 4 ϫ10 6 bp and one bacterium per CFU. PCR setup with crude lysates was performed under BSL-2 conditions, and all other manipulations were performed under BSL-1 controls with universal PCR precautions.
Phenotypic drug susceptibility testing. Each JHH isolate was tested for phenotypic resistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), and streptomycin (STR) using the MGIT-960 system as per the manufacturer's recommendations (Becton, Dickinson, Sparks, MD), and 1% agar proportion as per the Clinical and Laboratory Standards Institute (CLSI) M24-A2 standards (20) . The MGIT-960 and agar proportion methods both have established breakpoints for drug susceptibility and resistance determinations. For a selected subset of strains (n ϭ 78), the TREK Sensititre MYCOTB assay (TREK Diagnostic Systems, Cleveland, OH) was used to establish a MIC for each drug.
Primers, probes, and synthetic DNA standards. Amplification primers and microarray probes were designed against M. tuberculosis genes and target codons shown in Table 1 . Genes and codons represent high-confidence mutations known to confer resistance to RIF, INH, EMB, or STR. Nine PCR primer pairs were designed to work together in a multiplex, asymmetric master mix, where one of the primers in each pair was synthesized with a Cy3 label and the resulting single-stranded, labeled amplicon was captured by one or more immobilized microarray probes. Only one amplification reaction is required per test. PCR primers were synthesized by standard phosphoramidite chemistry at Akonni or Eurofins MWG Operon (Huntsville, AL), purified by high-performance liquid chromatography (HPLC), and quantified by UV absorption before use. The resulting Cy3-labeled, asymmetric amplicons ranged from 92 to 139 nucleotides (nt) in length.
Microarray probes were synthesized by Akonni with a custom 3= linker and purified to Ͼ90% purity by HPLC before use. Probe purity was measured by electrospray ionization-mass spectrometry. Each microarray contained a universal hybridization probe for each functional gene and primer pair to verify that the M. tuberculosis gene targets were amplified from each sample. At least one matched pair of microarray probes (wild type [WT] and single-nucleotide mutant [MU]) was included for each mutation of interest. Control probes included a Cy3 beacon for manufacturing quality control and positional reference, a synthetic hybridization control probe with no known homology to any naturally occurring sequence, and a probe for the M13 internal amplification and inhibition control. A 92-base, Cy3-labeled hybridization control target was synthesized by TriLink Biotechnologies (San Diego, CA), HPLC purified to Ͼ90% purity, and diluted to 100 pg ml Ϫ1 in 10 mM Tris, 1 mM Na 2 EDTA (pH 7.5).
Microarray manufacture. Gel element arrays were manufactured on custom-coated glass substrates by a single-step copolymerization procedure using a 4% 2-hydroxyethyl methylacrylamide copolymer, essentially as described in reference 21. Cy3 beacons were immobilized at 1 M, and all other probes were immobilized at 50 M. Up to three microarrays were printed on each glass substrate, but only one microarray is required per test. All microarrays were visually inspected for gel element presence and uniform morphology before use. Microarrays were stored at room temperature in a dust-free container until use (Ͻ1 month). Immediately before use, a 50-l gasket was applied around each microarray.
Multiplex, asymmetric amplification. Amplification reactions were assembled in 0.2-ml thin-walled PCR tubes and cycled on Quanta Biotech QB-96 thermal cyclers (Surrey, United Kingdom). The nine pairs of forward and reverse primers were combined in 1:10 ratios and prepared as a concentrated master mix to achieve a final primer concentration of 0.04 to 0.4 M each per reaction. Each 50-l reaction mixture contained 3 l of template (crude lysate or purified DNA), 25 l Qiagen multiplex PCR kit all-in-one amplification buffer and enzyme (Valencia, CA), 18 l asymmetric PCR primer mix, 5% dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO), and 0.6 g l Ϫ1 nonacetylated bovine serum albumin (Sigma-Aldrich). One microliter of M13 internal positive control (250 fg total) was included in all reaction mixtures, unless otherwise noted. The balance of each reaction was made up with sterile, ultrapure water as required. Notemplate controls containing the M13 internal positive control were processed in parallel for each set of experiments. The thermal cycling program consisted of an initial denaturation at 95°C for 15 min, followed by 40 cycles of 94°C for 30 s, 60°C for 60 s, and 72°C for 30 s, and a final extension at 72°C for 3 min. The actual run time for thermal cycling was ϳ2 h. Amplified material was either used immediately for microarray hybridization or stored at Ϫ20°C until use.
Hybridization and detection. After amplification, 20 l of unpurified amplicon was combined with 30 l of a concentrated hybridization master mix to achieve a final reaction mixture consisting of 1 M guanidine thiocyanate, 50 mM HEPES (pH 7.5), 5 mM Na 2 EDTA (pH 8.0), 3.3 g l Ϫ1 nonacetylated bovine serum albumin (BSA), and 4 fmol l Ϫ1 Cy3-labeled internal hybridization control. Forty-nine microliters of the resulting mixture was applied directly to the center of each microarray, and microarrays were covered with a Parafilm coverslip and hybridized for 3 h at 55°C on an MJ Research PTC-225 slide tower. After hybridization, coverslips and gaskets were removed, and up to 24 microarrays were washed simultaneously in 350 ml 1ϫ SSPE (150 mM NaCl, 10 mM NaH 2 PO 4 · H 2 O, 10 mM Na 2 EDTA), 0.01% Triton X-100 (pH 7.4) for 10 min with gentle agitation. Arrays were then dipped twice in ultrapure water and dried with compressed air.
Imaging and data analysis. Dried microarrays were imaged on an Akonni field-portable microarray analyzer, a very simple imager consist- ing of a high-intensity green-light-emitting diode (LED), custom optics, and noncooled charge-coupled device (CCD) camera. Image acquisition ranged from 0.05 to 0.1 s per array, and pixel data were acquired from raw .tif images using Spotfinder (J. Craig Venter Institute) software and a fixed-circle algorithm (mask size ϭ 25 pixel diameter) with all background pixels included in the analysis (top background cutoff value in Spotfinder set to zero). Local background was subtracted from the signal of each gel element. Integrated (background-corrected) signal intensity data were exported as tab-delimited text and imported into custom Excel spreadsheets for data analysis. Signal-to-noise ratios (SNRs) were calculated using the background-corrected signal from gel elements and normalizing against 3 times the standard deviation of the average local background.
A test was declared valid only if the average Cy3 beacon, internal hybridization control, and M13 amplification/inhibition control probes all generated SNRs of Ն3. Otherwise, the test was deemed invalid and test results were not reported. The IS6110 and IS1245 probes are internal positive controls, a proxy for detecting members of the M. tuberculosis and Mycobacterium avium complexes, respectively, and are used to condition the report for RIF, INH, EMB, and STR resistance-conferring mutations. Positive detection of both the IS6110 and IS1245 probes was considered to indicate a mixed sample. For all valid tests, if the IS1245 probe for M. avium complex (MAC) is detected, then no genotyping results are reported for the M. tuberculosis resistance-conferring mutations. Otherwise, discrimination ratios (D) were calculated for valid tests as (SNR WT Ϫ SNR MU )/(SNR WT ϩ SNR MU ). As currently implemented, a zero-copy IS6110 isolate will still generate discrimination ratios for M. tuberculosis resistance-conferring mutations, because the PCR primers for rpoB, inhA, katG, embB, and rpsL are specific for M. tuberculosis. For this study, any value of D of Ն0 was interpreted as a wild-type sequence at the targeted nucleotide position, and any value of D of Ͻ0 was interpreted as a mutation at the targeted nucleotide position. Results from this study were intended, in part, to understand and refine values for D that should correspond to an inconclusive test result before automating the image and data analysis algorithms for a clinical user and prospectively testing the microarray with decontaminated sediments or raw sputum samples.
If either IS1245 or IS6110 was detected at an SNR of Ն20, then the output from the internal control probes was reported as "not applicable." Deferring the interpretation of internal controls in the event of an "M. tuberculosis" or "MAC detected" result is based on the fact that the M13 internal positive control is included at a concentration very near its limit of detection. In cases where there is a very high concentration of M. tuberculosis DNA in the asymmetric PCR, there may be preferential amplification of the M. tuberculosis genes such that asymmetric M13 amplification is limited, and the M13 SNR is Ͻ3 (i.e., not detected).
RESULTS
Analytical sensitivity. Analytical sensitivity for correct genotyping was estimated by preparing a dilution series of quantified H37Ra DNA between 1 ng and 10 fg per test and performing the test in triplicate. Reproducible detection and correct genotyping was obtained between 500 fg and 1 pg DNA per test, or between 110 and 225 genome copies. At 500 fg, discrimination ratios (D) for the rpoB mutation 531W were between Ϫ0.07, and Ϫ0.12, and one of three replicates for the rpoB mutation 531C2 resulted in a D value of Ϫ0.03. In the absence of an indeterminate threshold for D, these values resulted in a false positive for RIF resistance. With a threshold D value of ՅϪ0.2 for declaring resistance (see Discussion), the estimated limit of detection for the test is between 500 fg and 100 fg, or 110 and 25 genome copies. The upper range for correct genotyping has not yet been determined, although the anticipated quantity of genomic DNA per test from positive-control and JHH clinical isolates (below) was estimated to be Ͼ5 ng per test, and we have anecdotal evidence that 100 ng M. tuberculosis DNA per test still leads to correct M. tuberculosis genotyping and behavior of the internal positive controls (data not shown). Opportunities for improving the lower limit of detection (LOD) are described below.
Analytical specificity. The M13 internal amplification and hybridization control was detected in all tests, and all no-template controls were consistently negative. The analytical specificity of the microarray test was evaluated with CDC and TDR isolates of known genotype, with results summarized in Table 2 . The 32 CDC and TDR isolates harbored 68 mutations in rpoB, inhA, katG, embB, and rpsL genes, six of which were not represented by a specific microarray probe. Of the 62 resistance-conferring mutations for which there was a sequence-specific probe on the microarray, the microarray correctly detected 95.2% of them (59/ 62), with false-negative genotyping results associated with the a *, identified mutation in the CDC or TDR isolate that is not represented by a mutation-specific probe on the microarray (n ϭ 6 near neighbor mutations). WT, wild type.
rpoB mutations Q513L and D516E. At least one near-neighbor probe was sensitive to three of the six known mutations that were not represented by a specific probe on the microarray, which is similar to the behavior of "sloppy molecular beacon" probes (22) . There were also 96 wild-type sequences interrogated by the microarray test, 100% of which were correctly identified as wild type.
Relative to phenotypic drug susceptibility tests, there was only one false-susceptible phenotypic result corresponding with the rpoB mutation D516E. These data demonstrate that the test can accurately detect resistance-conferring mutations when a mutationspecific probe is present on the microarray and provided the impetus for testing the system on blinded clinical isolates.
Blinded clinical isolates.
Of the 153 blinded clinical isolates from the JHH archive, phenotypic resistance to the first-line drugs RIF, INH, and EMB was detected by agar proportion in 40, 14, and 10 strains, respectively. Resistance was confirmed on these strains using the MGIT-960 system. Additional testing was performed on selected strains to determine MICs for the individual antibiotics, resulting in 459 data points that served as the phenotypic drug susceptibility test (DST) comparator for microarray system performance.
Overall concordance between agar proportion and the microarray test for the first-line drugs was 95.4% (146/153) for RIF, 96.1% (147/153) for INH, 96.7% (148/153) for EMB, and 96.1% (441/459) for the three drugs combined. There was no obvious difference in concordance when isolates were segregated by geographical origin or year of collection.
The percentage of false-resistant or false-susceptible results for all drugs is shown in Table 3 , and discrepant analysis relative to DNA sequencing is shown in Table 4 . Microarray sensitivity (true resistance) for the first line drugs was 100% for RIF (14/14), 90.0% for INH (36/40) and 70% for EMB (7/10). Overall microarray sensitivity for RIF, INH, and EMB combined was 89.1% (57/64). Microarray specificity (true susceptibility) was 95.0% for RIF (132/139), 98.2% for INH (111/113), and 98.6% for EMB (141/ 143). Overall microarray specificity for RIF, INH, and EMB combined was 97.2% (384/395). The overall positive and negative predictive values for RIF, INH, and EMB combined were 84.9% and 98.3%, respectively. MICs for isolates that had a false-susceptible microarray result for INH or EMB were well above established breakpoints for each drug and ranged from 0.5 g ml Ϫ1 to 4.0 g ml Ϫ1 for INH and Ͼ5.0 g ml Ϫ1 to 16.0 g ml Ϫ1 for EMB (Table  4) ; there were no false-susceptible microarray results for RIF.
A total of 153 phenotypic data points were collected for STR, which is now considered a second-line drug. Phenotypic STR resistance was detected in 23 of the 153 strains. Overall concordance between agar proportion and the microarray was 89.5% (137/ 153). Sensitivity was 34.8% (8/23) and specificity was 99.2% (129/ 130). Nine of the 10 isolates correctly identified as STR resistant by the microarray test had STR MICs of Ն32 g ml Ϫ1 , and one strain had an MIC of 4 g ml Ϫ1 . There was only one false-resistant STR result (0.65%) but 15 (9.8%) false-susceptible results. All other STR resistant isolates (n ϭ 15) for which false-susceptible errors occurred had MICs ranging from 4 g ml Ϫ1 to 8 g ml Ϫ1 . There were 33 discrepant phenotypic results between the microarray and the standard phenotypic tests, but there were only two discrepant results based on DNA sequence (Table 4) . Two RIF false-resistant calls (isolates S15 and CM161) involved a fairly weak microarray discrimination ratio (D) that may be best categorized as indeterminate; identifying an indeterminate range for D was an explicit objective of this study. All false-sensitive discrepant results were a consequence of DNA mutations that are not represented by a specific microarray probe. These data demonstrate that, from a DNA sequencing and hybridization perspective, the microarray is very specific and provides the correct multidrug resistance genotype 98.7% of the time when the resistance-conferring mutation is present in both the genome and the microarray (i.e., in 151/153 isolates).
There were 220 total tests (including negative controls) performed during the course of this study, with zero invalid tests. Six amplified samples were rehybridized to confirm the initial test result due to observed physical damage on one or more gel elements on an array, and one amplified sample was rehybridized due to a fluorescent artifact. The overall microarray hybridization repeat rate was therefore 3.2% (7/220). Gel element damage normally occurs as the user is removing the Parafilm coverslip before washing microarrays in a bulk solution. It is fully anticipated that physical gel element damage will be reduced or eliminated once the method is converted into an entirely closed consumable format.
DISCUSSION
Analytical sensitivity. In the absence of any threshold values for D, the lower limit of detection for the microarray test described here is at least 110 gene copies per amplification reaction, which is very near the limits of molecular sampling error in conventional exponential PCR (23) . Provided that a user can purify genomic DNA from primary specimens at Ͼ10% efficiency, there is no reason that the method or test as described cannot be applied to smear-positive sputum or decontaminated sediments that are expected to contain at least 10 3 to 10 4 CFU ml Ϫ1 . Based on this study, we identified several fairly simple ways in which the lower LOD of the test can be improved or stabilized. We have anecdotal evidence, for example, that increasing the hybridization temperature from 55°C to 57°C can resolve the false-positive rpoB signals at 100 to 500 fg input DNA. It is also possible to increase the number of amplification cycles, at the expense of increasing the total analysis time. Neither of these approaches was specifically addressed during the course of this study, because a 110-genome-copy limit of detection was deemed sufficiently sensitive to evaluate microarray specificity.
Analytical specificity. The analytical specificity of the microarray test is defined by the specificity of probe hybridization to cognate DNA sequences (Tables 2 and 4 ) rather than microarray response relative to phenotypic drug susceptibility results (Table 3) . In this context, the analytical specificity of the microarray test was excellent for both the control and blinded clinical isolates. The most weakly performing probes were those for the rpoB mutations Q513L and D516E, for which hybridization signal intensity was lower than that of neighboring or related probes regardless of probe design (sequence length and single-nucleotide polymorphism [SNP] position within the probe) or gel element polymer composition (data not shown). The rpoB single-stranded amplicon is predicted to have significant stem-loop secondary structure in the 513-to-516 region using Mfold (24) , and it is well known that secondary and tertiary structures can negatively influence hybridization sensitivity and specificity (25, 26) . Fortunately, both Q513L and D516E are relatively rare mutations conferring resistance to RIF, and the consequence of weak hybridization is manifest primarily in analytical sensitivity, not specificity. It is usually assumed that hybridization specificity needs to be perfect in order for microarrays to have diagnostic value. On the other hand, "sloppy molecular beacons" that are responsive to multiple mutations within a 20-mer reporting probe (22) form the basis of the GeneXpert MTB/RIF assay and enable reasonably sensitive detection (but not identification) of mutations regardless of where the mutation occurs within the reporting probe.
Most of the microarray probes were very specific for their corresponding mutation and insensitive to near-neighbor mutations (Table 2 ), but some probes were not 100% specific. The clinical importance of perfect versus sloppy hybridization specificity ultimately depends on the information needed to provide patientspecific antibiotic therapy. For example, if the clinical decision to treat with RIF is based on the presence of any mutation in the rpoB gene, then sloppy hybridization and reporting probes are adequate for diagnostic purposes. On the other hand, if the clinical outcome of RIF treatment ultimately depends on epistatic interactions or compensatory mutations within the rpoB gene (27) (28) (29) (30) , then it may be important to identify precisely which mutations are present before making a decision to treat or not treat with RIF. This situation was evident in the analysis of the RIF phenotypic discrepant isolates in Table 4 . Isolate C9, for example, was sensitive to RIF (MIC Ͻ 0.12) but the microarray reported discrimination ratios (D) of Ϫ0.71, Ϫ0.60, and Ϫ0.40 for the mutations H526N, H526Y, and H526R, respectively. That multiple 526 probes reported a mutation at codon 526 demonstrates that these probes are somewhat sloppy, as mentioned above. The discrepancy between phenotypic and DNA sequence results points to a compensatory mutation or epistatic interactions leading to RIF susceptibility. Given the way in which hybridization signals are calculated and compared, we are able to specifically identify the corresponding 526 mutation, because the actual mutation corresponds to the probe with the lowest discriminant ratio (H526N, D ϭ Ϫ0.71). Similar results and conclusions were obtained for isolates 66 and C10 (Table 4) . If future clinical research finds that the clinical manifestation of mutation H526N or H526Y is prone to epistatic effects, or that RIF resistance due to H526N or H526Y mutations can be overcome by compensatory mutations elsewhere in rpoB or the M. tuberculosis genome, then it is important to specifically identify the rpoB genotype at multiple codon positions before proscribing RIF. These data show how a microarraybased diagnostic and discriminant ratio for each detectable mutation can offer clear clinical advantages over nonspecific molecular beacons or line probe assays that rely on subjective interpretation of reporter signal intensities.
One of the technical objectives of this study was to identify preliminary ranges for D that should result in an indeterminate test output. For example, RIF false-resistance determinations for isolates S15 and CM161 are derived from D values of Ϫ0.17 and Ϫ0.13, respectively, both of which are weak discrimination ratios. Weak discriminant ratios mean that the hybridization signals on the wild-type and corresponding mutant probes are nearly identical and could result from a degraded sample, target nucleic acids near the limit of detection for the test (see above), or a potential mixture of two or more genotypes. Based on the results of this study, we anticipate that D values between Ϫ0.2 and 0.0 should be considered indeterminate results for declaring a mutation present, subject to retesting or follow-up analyses. Verifying these ranges for an indeterminate test output will require prospective trials on a much larger set of isolates and primary clinical samples.
Clinical potential and drug susceptibility correlates. Most clinical algorithms intended to diagnose drug-resistant M. tuberculosis still include a culture confirmation step, and the resulting culture must still be tested for susceptibility to other first-or second-line drugs using conventional phenotypic DST. Since the analytical performance of the microarray-based system developed here is consistent with other WHO-endorsed diagnostic tests, it may therefore add value at that point in a clinical diagnostic algorithm at which a primary culture tests positive for M. tuberculosis but which is weeks to months before culture-based, phenotypic DST results are obtained. We also suggest that there is clinical value in specifically identifying drug resistance mutations relative to conventional measures of DST breakpoints, regardless of the prevalence of the genotypes or mutations in selected populations.
For example, false-positive RIF resistance has also been documented for the MTBDRplus and Xpert MTB/RIF assays (31, 32) , meaning that mutations associated with resistance were detected in rpoB, yet the strains were phenotypically susceptible using several standardized susceptibility testing methods and DST breakpoints. In a follow-up study (33) , false-positive Xpert MTB/RIF resistance was associated with low-level phenotypic resistance that was below the established critical concentration for RIF (1.0 g ml Ϫ1 ) but often within one doubling dilution of the critical concentration.
Since the incidence of genotypic false-positive RIF resistance depends on the prevalence of RIF resistance in a given population (34, 35) , the unresolved clinical questions are how to accurately correlate genotype with drug susceptibility phenotypes while fulfilling the medical community's requirements for and desired attributes of a rapid molecular TB test (3, 36, 37) . The answer to these questions is especially important when the prevalence of drug resistance in a population is low (Ͻ5%), when RIF resistance alone is used as a surrogate marker for MDR M. tuberculosis, or when the availability of second-line drugs is limited.
Toward point of use. The purpose of this study was to establish the analytical performance characteristics of a simplified microarray method for detecting drug-resistant M. tuberculosis before integrating the approach into a closed-amplicon consumable and automated sample-to-answer system that can be deployed beyond reference laboratories. It is nevertheless inevitable that comparisons will be made between the results of this study and clinical expectations for and opinions about a molecular diagnostic that is intended to initiate treatment with antibiotics in the field.
Knowledge of the full spectrum of mutations that cause drug resistance in M. tuberculosis is relatively complete only for RIF. Ongoing M. tuberculosis DNA sequencing projects will identify many more genes and mutations that correlate with drug resistance, and other studies will eventually identify the resistance mechanisms caused by these mutations. Even before these exploratory studies are complete, however, we know that silent mutations (38) and some "disputed" mutations are indeed rather common and clinically relevant (39) . Thus, it is already clear that detect-to-treat TB diagnostic tests will necessarily require higher levels of multiplexing than are presently available by real-time PCR and will require a capability to specifically identify the mutations that are present. It is for this reason that microarrays are still an attractive platform for developing resource-appropriate diagnostics.
In this study, the initial technical aspects of simplifying microarray workflow for translation into an automated, point-ofuse system are reflected in (i) a single-tube multiplex PCR that simultaneously incorporates a fluorescent label and generates predominantly short, single-stranded DNA targets for hybridization, (ii) a direct transfer of amplified material to the hybridization reaction mixture without any postamplification cleanup or target fragmentation, and (iii) relatively short hybridization and wash times. The sample-to-answer test was readily performed in a PCRcompatible laboratory environment with no cross contamination, enabled routine processing of 24 samples per 8-hour shift by one operator, and resulted in an analytical sensitivity of at least 110 genomes, which is more than sufficient for the analysis of smearpositive clinical specimens. The procedural simplifications de-scribed here are very conducive to translating the test into an entirely closed-amplicon, all-in-one consumable (40) , which is the logical next step in microarray technology development and is conceptually similar to the translation of PCR into real-time PCR, which contributed to the acceptance of PCR as a diagnostic tool in clinical laboratory environments.
A point-of-care intended use, however, does have technical implications that were not addressed as part of this study. For example, we did not address the technical challenges of nucleic acid extraction and purification from raw sputum, performing a sample-to-answer test under BSL-1 conditions, reducing the total analysis time to Ͻ3 h, providing prepackaged reagents and consumables that have a 24-month shelf life at 30°C and in the absence of cold storage, converting the instrumentation into an allin-one device that can operate from a battery, or manufacturing commercially available, nonsubsidized tests for less than $10 (U.S.) each (3, 36, 37) .
In this context, it is reasonable to ask whether any one technology or platform can possess all of these desired attributes, given the biological and molecular complexity of drug-resistant M. tuberculosis and its diagnostic or technological implications. Relative to translational potential of the gel element microarray method reported here, we note that the 8-hour total analysis time is a reflection of our desire for internal consistency in comparing the results of this study with preliminary data and quality control methods, rather than an absolute minimum time requirement for performing the test. For example, it may be entirely possible to reduce the 3-h hybridization time to 10 to 15 min without a loss in analytical sensitivity, since the test amplifies target nucleic acids and the hybridization step is already conducted under nonequilibrium hybridization conditions. Likewise, M. tuberculosis cultures and smear-positive sputum samples have enough M. tuberculosis DNA per amplification reaction that the total number of amplification cycles could be significantly reduced without affecting genotyping specificity. We have retained 40 amplification cycles (ϳ2 h) as a prelude to detecting drug-resistant M. tuberculosis in smear-negative, culture-positive specimens, for which there is a tremendous unmet clinical need. Methods and systems for automated nucleic acid extraction from primary specimens (sputum and sediment) are under development and will be reported elsewhere. In the interim, results from this study indicate that the gel element microarray and simplified method are analytically robust and ready for integration into an all-in-one, closed-amplicon microarray format (17) , which is a technology requirement and precursor for a point-of-use, fully integrated, drug-resistant-M. tuberculosis diagnostic system and platform.
